This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 11/02/2026
| Characteristic | POLLUX | MAIA | ||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, ITT population (n=286) | D-Rd, discontinued R±d (n=73) | D-Rd, ITT population (n=368) | |
| Median age (range), years | 65.5 (45-82) | 65.0 (34-89) | 75.0 (66-85) | 73.0 (50-90) |
| Distribution, n (%) | ||||
| <65 | 20 (48) | 133 (47) | 0 | 4 (1) |
| 65-74 | 16 (38) | 124 (43) | 36 (49) | 204 (55) |
| ≥75 | 6 (14) | 29 (10) | 37 (51) | 160 (44) |
| Baseline ECOG PS score, n (%) | ||||
| 0 | 10 (24) | 139 (49) | 27 (37) | 127 (35) |
| 1 | 27 (64) | 136 (48) | 35 (48) | 178 (48) |
| ≥2 | 5 (12) | 11 (4) | 11 (15) | 63 (17) |
| Cytogenetic abnormalitiesa | ||||
| N | 35 | 228 | 65 | 319 |
| Standard risk, n (%) | 30 (86) | 193 (85) | 57 (88) | 271 (85) |
| High risk, n (%) | 5 (14) | 35 (15) | 8 (12) | 48 (15) |
| Frailty scoreb | ||||
| Nonfrail | - | - | 36 (49) | 196 (53) |
| Frail | - | - | 37 (51) | 172 (47) |
| ISS disease stage,c | ||||
| I | 17 (41) | 137 (48) | 22 (30) | 98 (27) |
| II | 16 (38) | 93 (33) | 34 (47) | 163 (44) |
| III | 9 (21) | 56 (20) | 17 (23) | 107 (29) |
| Abbreviations: D-Rd, DARZALEX + lenalidomide + dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; ISS, International Staging System; ITT, intent-to-treat; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone. aCytogenetic abnormalities (del17p, t[14;16], or t[4;14]) were based on FISH or karyotype testing. Percentages were calculated with the number of patients in each treatment arm as the denominator. bFrailty score is available only for MAIA and is based on the scoring system in the FIRST trial5 cISS staging is derived based on the combination of serum ß2-microglobulin and albumin. | ||||
| POLLUX | MAIA | |
|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, discontinued R±d (n=73) | |
| Reasons for lenalidomide discontinuation, n (%) | 41 (98)a | 73 (100) |
| AE | 38 (90) | 67 (92) |
| Otherb | 3 (7) | 6 (8) |
| Most common (≥10%) reasons for discontinuation of lenalidomide or dexamethasone due to AEs, n (%) | ||
| Diarrhea | 5 (12) | 16 (22) |
| Neutropenia | 6 (14) | 9 (12) |
| Fatigue | 8 (19) | 5 (7) |
| Abbreviations: AE, adverse event; D-Rd, DARZALEX + lenalidomide + dexamethasone; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone. aReason for discontinuing lenalidomide in POLLUX was not captured for 1 patient whose discontinuation was due to “withdrawal by subject.” bIncludes patient decision to discontinue, interruption due to AEs caused by progressive disease or other conditions, or cumulative low-grade AEs. | ||
In POLLUX, amongst patients that discontinued R±d:
In MAIA, amongst patients that discontinued R±d:
| TEAEs, n (%) | POLLUX | MAIA | ||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, discontinued R±d (n=73) | |||
| Any gradea | Grade 3/4 | Any gradea | Grade 3/4 | |
| Hematologic | ||||
| Anemia | 18 (43) | 8 (19) | 22 (30) | 8 (11) |
| Leukopenia | 5 (12) | 2 (5) | 19 (26) | 11 (15) |
| Lymphopenia | 4 (10) | 3 (7) | 14 (19) | 11 (15) |
| Neutropenia | 30 (71) | 27 (64) | 45 (62) | 42 (58) |
| Thrombocytopenia | 15 (36) | 7 (17) | 9 (12) | 5 (7) |
| Nonhematologic | ||||
| Cataract | 11 (26) | 1 (2) | 16 (22) | 8 (11) |
| Diarrhea | 25 (60) | 6 (14) | 52 (71) | 7 (10) |
| Fatigue | 22 (52) | 8 (19) | 30 (41) | 9 (12) |
| Hyperglycemia | 4 (10) | 2 (5) | 11 (15) | 8(11) |
| Hypokalemia | 11 (26) | 4 (10) | 19 (26) | 8 (11) |
| Pneumonia | 13 (31) | 9 (21) | 18 (25) | 10 (14) |
| Pulmonary embolism | 1 (2) | 0 | 8 (11) | 8 (11) |
| Abbreviations: D-Rd, DARZALEX + lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone TEAE, treatment-emergent adverse event. aAny grade TEAEs are shown for reference. | ||||
| MAIA | ||||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=73) | D-Rd, continued R±d (n=295) | D-Rd, ITT population (n=368) | Rd, ITT population (n=369) | |
| At 12-month landmark, % | n=71 | n=238 | n=309 | n=254 |
| 24-month PFS rate | 88.7 | 88.0 | 88.2 | 78.5 |
| 36-month PFS rate | 78.4 | 78.7 | 78.6 | 59.1 |
| At 24-month landmark, % | n=63 | n=203 | n=266 | n=193 |
| 36-month PFS rate | 88.4 | 89.4 | 89.1 | 75.7 |
| Abbreviations: D-Rd, DARZALEX + lenalidomide + dexamethasone; ITT, intent-to-treat; PFS, progression-free survival; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone. | ||||
| POLLUX | ||||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, continued R±d (n=244) | D-Rd, ITT population (n=286) | Rd, ITT population (n=283) | |
| At 12-month landmark, % | n=40 | n=189 | n=229 | n=160 |
| 24-month PFS rate | 92.3 | 79.2 | 81.5 | 66.9 |
| 36-month PFS rate | 76.2 | 63.1 | 65.3 | 46.9 |
| At 24-month landmark, % | n=36 | n=148 | n=184 | n=102 |
| 36-month PFS rate | 82.5 | 79.6 | 80.2 | 70.2 |
| 48-month PFS rate | 76.2 | 70.0 | 71.2 | 52.3 |
| Abbreviations: D-Rd, DARZALEX + lenalidomide + dexamethasone; ITT, intent-to-treat; PFS, progression-free survival; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone. | ||||
| POLLUX | MAIA | ||||
|---|---|---|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, discontinued R±d after ≥12 months (n=30) | D-Rd, discontinued R±d (n=73) | D-Rd, discontinued R±d after ≥12 months (n=53) | ||
| At median follow-up, % | 54.8 months | 36.4 months | |||
| 24-month PFS rate | 90.1 | 90.0 | 86.3 | 94.3 | |
| 36-month PFS rate | 74.3 | 79.5 | 76.3 | 80.8 | |
| Abbreviations: D-Rd, DARZALEX + lenalidomide + dexamethasone; PFS, progression-free survival; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone. | |||||
| Response Rate, n (%) | POLLUX | |||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=42) | D-Rd, discontinued R±d after ≥12 months (n=30) | D-Rd, ITT population (n=286) | Rd, ITT population (n=283) | |
| ≥CR | 30 (71) | 25 (83) | 162 (58)a | 65 (24)a |
| ≥VGPR | 38 (90) | 29 (97) | 228 (81)a | 136 (49)a |
| ≥PR | 41 (98) | 30 (100) | 261 (93)a | 211 (76)a |
| Abbreviations: CR, complete response; D-Rd, DARZALEX + lenalidomide + dexamethasone; ITT, intent-to-treat; MM, multiple myeloma; PR, partial response; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone; VGPR, very good partial response.aResponse-evaluable set (D-Rd, n = 281; Rd, n = 276). Response-evaluable was defined as patients with confirmed diagnosis of MM and measurable disease at baseline or screening visit. In addition, patients must have received ≥1 dose of study treatment and have≥1 post-baseline disease assessment. | ||||
| Response Rate, n (%) | MAIA | |||
|---|---|---|---|---|
| D-Rd, discontinued R±d (n=73) | D-Rd, discontinued R±d after ≥12 months (n=53) | D-Rd, ITT population (n=368) | Rd, ITT population (n=369) | |
| ≥CR | 33 (45) | 30 (57) | 182 (49) | 100 (27) |
| ≥VGPR | 66 (90) | 50 (94) | 295 (80) | 203 (55) |
| ≥PR | 73 (100) | 53 (100) | 342 (93) | 301 (82) |
| Abbreviations: CR, complete response; D-Rd, DARZALEX + lenalidomide + dexamethasone; ITT, intent-to-treat; MM, multiple myeloma; PR, partial response; Rd, lenalidomide + dexamethasone; R±d, lenalidomide with or without dexamethasone; VGPR, very good partial response. | ||||
A literature search of MEDLINE®
| 1 | Dimopoulos M, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331. |
| 2 | |
| 3 | |
| 4 | |
| 5 |
Would you like to clear and leave your conversation? Message history will be lost.